Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients

Completed

• Conditions: Critically ill patients with severe infection; Infections and Infestations

• Registration Number: ISRCTN26147641
• Lead Sponsor: Charles University Teaching Hospital Plzen (Czech Republic)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2012-01-20
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

1. Patients aged 18 years and over
2. Admitted to the interdisciplinary Intensive Care Unit (ICU) between September 2007 and May 2010
3. Had suffered from severe infection and received meropenem with predicted duration of treatment for at least 4 days at the admission or during the ICU stay
4. Types of infections include:
4.1. Abdominal
4.2. Respiratory
4.3. Skin
4.4. Soft tissue
4.5. Bloodstream
4.6. Central nervous system
4.7. Urinary tract
4.8. Other sources of infections

Exclusion Criteria

1. Age younger than 18 years
2. Pregnancy
3. Acute or chronic renal failure with glomerular filtration rate lower than 0.5 ml/s
4. Immunodeficiency or immunosuppressant medication
5. Neutropenia
6. Hypersensitivity or allergy to meropenem

Study & Design

• Study Type: Interventional
• Study Design: Not specified